Short answer
Alnylam Pharmaceuticals (ALNY) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2.5B (up 217.7% year over year) with net income of $370M.
Q2 2026 key financials · XBRL
- Revenue
- $2.5B
- +217.7% YoY
- Net income
- $370M
- +659.0% YoY
- Operating margin
- 20.3%
- EPS (diluted)
- $2.71
- +631.4% YoY
Source: XBRL data from the Alnylam Pharmaceuticals (ALNY) Q2 2026 10-Q on SEC EDGAR. USD.
Alnylam Pharmaceuticals Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- AMVUTTRA revenue $1.01B; ONPATTRO $18.5M; GIVLAARI $89.8M; OXLUMO $52.1M in Q2 2026
- Best product AMVUTTRA at $1.01B; lowest product ONPATTRO at $18.5M
- 2028 Notes issuance $661.3M; capped-call payment $35.3M; 2027 Note repurchases totaled approximately $1.16B
- Management targets 25%+ revenue CAGR and approximately 30% non-GAAP operating margin through 2030; continued significant R&D investment expected
Risk Factors
- New AMVUTTRA concentration risk triggered by FDA approval for ATTR-CM in March 2025; sales comprised significant product revenue in 2025 and six months ended June 30, 2026
- Most material commercial update: AMVUTTRA net product revenues reached $1.17 billion in Q2 2026 and $2.21 billion year-to-date
- Regulatory risk from evolving drug-pricing rules, including potential U.S. government price negotiation and most-favored-nation measures
- Competitive risk from additional ATTR-CM therapies or generic competing products reducing AMVUTTRA adoption and reimbursement
- Financial risk from $3.31 billion in cash, equivalents and marketable securities exposed to credit, liquidity, market and interest-rate losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alnylam Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.